Congestive heart failure: Difference between revisions
Jump to navigation
Jump to search
| (12 intermediate revisions by 4 users not shown) | |||
| Line 8: | Line 8: | ||
{{Congestive heart failure}} | {{Congestive heart failure}} | ||
{{CMG}}; {{AE}} {{LG}}, {{MehdiP}} {{HK}} | {{CMG}}; {{AE}} {{LG}}, {{Mitra}} {{MehdiP}} {{HK}} [[User:Edzelco|Edzel Lorraine Co, D.M.D., M.D.]] [Mailto:efco@alum.up.edu.ph] | ||
{{SK}} CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF | {{SK}} CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF | ||
| Line 35: | Line 35: | ||
== Treatment == | == Treatment == | ||
=== Treatment of Heart failure with reduced ejection fraction === | === Treatment of Heart failure with reduced ejection fraction === | ||
: '''[[Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction|Pharmacological treatments for patients with heart failure with reduced ejection fraction]]''': | : '''[[Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction|Pharmacological treatments for patients with heart failure with reduced ejection fraction]]''': | ||
*'''In all patients:''' [[Congestive heart failure Angiotensin-converting enzyme inhibitors|Angiotensin-converting enzyme inhibitors]] | [[Congestive heart failure beta blockers|Beta Blockers]] | [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]] | [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]] | [[Congestive heart failure Sodium-glucose co-transporter 2 inhibitors|Sodium-glucose co-transporter 2 inhibitors]] | |||
*'''In selected patients:''' [[Congestive heart failure diuretics|Diuretics]] | [[Congestive heart failure angiotensin receptor blockers|Angiotensin receptor blockers]] | [[Congestive heart failure If-channel inhibitor|I<sub>f</sub>-channel inhibitor]] | [[Combination of hydralazine and isosorbide dinitrate]] | [[Congestive heart failure Digoxin|Digoxin]] | [[Congestive heart failure iron|Iron]] | |||
Guideline-recommended medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) can be suggested by the [https://decisionalgorithm.shinyapps.io/heartfailure/ Heart Failure Educational Decision Aid] medication optimization algorithm<ref name="DorschSifuentesCordwin2023">{{cite journal | last1 = Dorsch | first1 = Michael P. | last2 = Sifuentes | first2 = Aaron | last3 = Cordwin | first3 = David J. | last4 = Kuo | first4 = Rachel | last5 = Rowell | first5 = Brigid E. | last6 = Arzac | first6 = Juan J. | last7 = DeBacker | first7 = Ken | last8 = Guidi | first8 = Jessica L. | last9 = Hummel | first9 = Scott L. | last10 = Koelling | first10 = Todd M. | title = A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction | journal = JACC: Advances | date = April 2023 | page = 100289 | issn = 2772-963X | doi = 10.1016/j.jacadv.2023.100289 | pmid = | url = }}</ref>. | |||
: '''Cardiac rhythm management for patients with heart failure with reduced ejection fraction''': [[Congestive heart failure Antiarrhythmic drugs|Antiarrhythmic drugs]] | [[Congestive heart failure Implantable cardioverter defibrillator|Implantable cardioverter defibrillator]] | [[Cardiac resynchronization therapy]] | : '''Cardiac rhythm management for patients with heart failure with reduced ejection fraction''': [[Congestive heart failure Antiarrhythmic drugs|Antiarrhythmic drugs]] | [[Congestive heart failure Implantable cardioverter defibrillator|Implantable cardioverter defibrillator]] | [[Cardiac resynchronization therapy]] | ||
: '''[[Congestive heart failure Nutritional supplements and hormonal therapies|Nutritional supplements and hormonal therapies]]''' | : '''[[Congestive heart failure Nutritional supplements and hormonal therapies|Nutritional supplements and hormonal therapies]]''' | ||
: '''[[Congestive heart failure Exercise training|Exercise training]]''' | |||
: '''[[Congestive heart failure Drugs to avoid|Drugs to avoid]]''' | : '''[[Congestive heart failure Drugs to avoid|Drugs to avoid]]''' | ||
: '''[[Congestive heart failure Drug interactions|Drug interactions]]''' | : '''[[Congestive heart failure Drug interactions|Drug interactions]]''' | ||
| Line 50: | Line 56: | ||
=== [[Congestive heart failure Management of Acute heart failure | Management of Acute heart failure]] === | === [[Congestive heart failure Management of Acute heart failure | Management of Acute heart failure]] === | ||
===[[ | ===[[ Management of Advanced heart failure]] === | ||
[[Congestive heart failure Ultrafiltration|Ultrafiltration]] | [[Congestive heart failure Mechanical circulatory support| Mechanical circulatory support]] | [[Heart transplantation]] | [[Congestive heart failure Ultrafiltration|Ultrafiltration]] | [[Congestive heart failure Mechanical circulatory support| Mechanical circulatory support]] | [[Heart transplantation]] | ||
== ACC/AHA Guideline Recommendations == | == ACC/AHA Guideline Recommendations == | ||
| Line 91: | Line 84: | ||
[[Congestive heart failure treatment of special populations|Special Populations]] | [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]] | [[Congestive heart failure treatment of special populations|Special Populations]] | [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]] | ||
==References== | ==References== | ||
Latest revision as of 22:20, 19 April 2023
 |
Resident Survival Guide |
| Congestive Heart Failure Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Congestive heart failure from other Diseases |
|
Diagnosis |
|
Treatment |
|
Medical Therapy: |
|
Surgical Therapy: |
|
ACC/AHA Guideline Recommendations
|
|
Specific Groups: |
|
Congestive heart failure On the Web |
|
Risk calculators and risk factors for Congestive heart failure |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2], Mitra Chitsazan, M.D.[3] Seyedmahdi Pahlavani, M.D. [4] Syed Hassan A. Kazmi BSc, MD [5] Edzel Lorraine Co, D.M.D., M.D. [6]
Synonyms and keywords: CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF
Overview
Classification
Pathophysiology
Systolic dysfunction | Diastolic dysfunction | HFpEF | HFrEF
Causes
Differentiating Chronic Heart Failure from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | Echocardiography | Cardiac MRI | Exercise Stress Test | Myocardial Viability Studies | Cardiac Catheterization | Invasive hemodynamic monitoring
Treatment
Treatment of Heart failure with reduced ejection fraction
- In all patients: Angiotensin-converting enzyme inhibitors | Beta Blockers | Aldosterone Antagonists | Angiotensin Receptor-Neprilysin Inhibitor | Sodium-glucose co-transporter 2 inhibitors
- In selected patients: Diuretics | Angiotensin receptor blockers | If-channel inhibitor | Combination of hydralazine and isosorbide dinitrate | Digoxin | Iron
Guideline-recommended medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) can be suggested by the Heart Failure Educational Decision Aid medication optimization algorithm[1].
- Cardiac rhythm management for patients with heart failure with reduced ejection fraction: Antiarrhythmic drugs | Implantable cardioverter defibrillator | Cardiac resynchronization therapy
- Nutritional supplements and hormonal therapies
- Exercise training
- Drugs to avoid
- Drug interactions
- Treatment of underlying causes
- Treatment of associated conditions
Treatment of Heart failure with preserved ejection fraction
Management of Acute heart failure
Management of Advanced heart failure
Ultrafiltration | Mechanical circulatory support | Heart transplantation
ACC/AHA Guideline Recommendations
Hospitalized Patients
Patients With a Prior MI
Sudden Cardiac Death Prevention
Stage A: Patients at High Risk for Developing Heart Failure
Treatment of Hypertension | Treatment of Diabetes Mellitus | Management of Metabolic Syndrome | Management of Atherosclerotic Disease | Control of Conditions That May Cause Heart Failure | ACC/AHA Guideline Recommendations
Stage B: Patients with Cardiac Structural Abnormalities
Stage C: Patients with Current or Prior Heart Failure Symptoms
Stage D: Patients with Refractory End-stage Heart Failure
Implementation of Practice Guidelines
End-Of-Life Considerations
Specific Groups
Special Populations | Patients who have concomitant disorders | Obstructive Sleep Apnea in the Patient with CHF
References
- ↑ Dorsch, Michael P.; Sifuentes, Aaron; Cordwin, David J.; Kuo, Rachel; Rowell, Brigid E.; Arzac, Juan J.; DeBacker, Ken; Guidi, Jessica L.; Hummel, Scott L.; Koelling, Todd M. (April 2023). "A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction". JACC: Advances: 100289. doi:10.1016/j.jacadv.2023.100289. ISSN 2772-963X.